Adipocytokines and the risk of ischemic stroke: The PRIME Study
Article first published online: 20 APR 2012
Copyright © 2011 American Neurological Association
Annals of Neurology
Volume 71, Issue 4, pages 478–486, April 2012
How to Cite
Prugger, C., Luc, G., Haas, B., Arveiler, D., Machez, E., Ferrieres, J., Ruidavets, J.-B., Bingham, A., Montaye, M., Amouyel, P., Yarnell, J., Kee, F., Ducimetiere, P., Empana, J.-P. and on behalf of the PRIME Study Group (2012), Adipocytokines and the risk of ischemic stroke: The PRIME Study. Ann Neurol., 71: 478–486. doi: 10.1002/ana.22669
- Issue published online: 20 APR 2012
- Article first published online: 20 APR 2012
- Accepted manuscript online: 25 NOV 2011 08:38AM EST
- Manuscript Accepted: 4 NOV 2011
- Manuscript Revised: 3 OCT 2011
- Manuscript Received: 28 JUN 2011
Adipocytokines are hormones secreted from adipose tissue that possibly link adiposity and the risk of cardiovascular disease, but limited prospective data exist on plasma adipocytokines and ischemic stroke risk. We investigated associations and predictive properties of 4 plasma adipocytokines, namely resistin, adipsin, leptin, and total adiponectin, with regard to incident ischemic stroke in the PRIME Study.
A cohort of 9,771 healthy men 50 to 59 years of age at baseline was followed up over a period of 10 years. In a nested case–control study, 95 ischemic stroke cases were matched with 190 controls on age, study center, and date of examination. Hazard ratios (HRs) per standard deviation increase in plasma adipocytokine levels were estimated using conditional logistic regression analysis. The additive value of adipocytokines in stroke risk prediction was evaluated by discrimination and reclassification metrics.
Resistin (HR, 1.88; 95% confidence interval [CI], 1.16–3.03), adipsin (HR, 2.01; 95% CI, 1.33–3.04), and total adiponectin (HR, 1.53; 95% CI, 1.01–2.34), but not leptin, were independent predictors of ischemic stroke. The performance of a traditional risk factor model predicting ischemic stroke was significantly improved by the simultaneous inclusion of resistin, adipsin, and total adiponectin (c-statistic: 0.673 [95% CI, 0.631–0.766] vs 0.826 [95% CI, 0.792–0.892], p < 0.001; net reclassification improvement: 38.1%, p < 0.001).
Higher plasma levels of resistin, adipsin, and total adiponectin were associated with an increased 10-year risk of ischemic stroke among healthy middle-aged men. Resistin, adipsin, and total adiponectin provided incremental value over traditional risk factors for the prediction of ischemic stroke risk. ANN NEUROL 2012;